Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 11/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19284595 | 1.00 | HTR6 (0.54) | HTR6HTR2CADRB2QDPRIDO1 | |
| SCHEMBL13004839 | 0.87 | IDO1 (0.56) | HTR6IDO1SLC6A4 | |
| SCHEMBL28835351 | 0.87 | IDO1 (0.56) | HTR6IDO1SLC6A4 | |
| SCHEMBL11007946 | 0.83 | IDO1 (0.52) | HTR6IDO1 | |
| SCHEMBL11002147 | 0.81 | IDO1 (0.53) | IDO1 | |
| SCHEMBL30735827 | 0.81 | HTR6 (0.56) | HTR6HTR2CADRB2SLC18A3SIGMAR1 | |
| SCHEMBL19284708 | 0.81 | HTR6 (0.56) | HTR6HTR2CADRB2SLC18A3SIGMAR1 | |
| SCHEMBL28710828 | 0.80 | IDO1 (0.48) | HTR6IDO1SLC6A4 | |
| Hydrochloric Acid SCHEMBL19284610 | 0.80 | HTR2C (0.56) | HTR6HTR2CADRB2SLC18A3SIGMAR1 | |
| SCHEMBL19284659 | 0.79 | HTR6 (0.54) | HTR6HTR2CADRB2SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | SRX CARDIO, LLC (US) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891369-B2 | Compounds for binding proprotein convertase subtilisin/kexin type 9 | PCSK9, PCSK6, PCSK7 | HTR6 2874/4885HTR2C 3255/4885ADRB2 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.